InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Mills Kenneth T., Chairman & CEO. Insider active across 1 companies, notably REGENXBIO Inc.. Aggregated, 12 filings have been recorded. The latest transaction was disclosed on 1 January 2022 — Retenue fiscale. Regulator: SEC (Form 4). All data is free.
Declarations12 total
€104,9863,636 shares@ €28.874175.8% of flow
Common Stock
SEC:0001562180-22-000149·
€104,9863,636 shares@ €28.87410.036% mcap37.9% of flow
Common Stock
SEC:0001562180-22-000149:0·
03,300 shares0
Common Stock
SEC:0001562180-21-007473·
03,300 shares0
Common Stock
SEC:0001562180-21-007473:0·
€4,8751,500 shares@ €3.25013.5% of flow
Common Stock
SEC:0001562180-21-006967·
€4,8751,500 shares@ €3.25010.0016% mcap1.8% of flow
Common Stock
SEC:0001562180-21-006967:0·
€4,8221,500 shares@ €3.21463.5% of flow
Common Stock
SEC:0001562180-21-006147·
€4,8221,500 shares@ €3.21460.0016% mcap1.7% of flow
Common Stock
SEC:0001562180-21-006147:0·
€9,5503,000 shares@ €3.18326.9% of flow
Common Stock
SEC:0001562180-21-005947·
€9,5503,000 shares@ €3.18320.0032% mcap3.4% of flow
Common Stock
SEC:0001562180-21-005947:0·
€14,1824,500 shares@ €3.151610.2% of flow
Common Stock
SEC:0001562180-21-004525·
€14,1824,500 shares@ €3.15160.0048% mcap5.1% of flow
Common Stock
SEC:0001562180-21-004525:0·
12 of 12 declarations
About Mills Kenneth T.
Kenneth T. Mills is the President and CEO of REGENXBIO Inc. He leads the company in its mission to develop innovative gene therapies for the treatment of serious genetic diseases. Under his leadership, REGENXBIO has focused on advancing its research and development programs aimed at improving patient lives. Kenneth T. Mills has extensive experience in the biopharmaceutical sector, enabling him to effectively guide the company in a constantly evolving environment.
